Back to Search
Start Over
Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.
- Source :
-
Gastroenterology [Gastroenterology] 2019 Jan; Vol. 156 (2), pp. 431-445. Date of Electronic Publication: 2018 Oct 17. - Publication Year :
- 2019
-
Abstract
- Chronic infection with hepatitis C virus is a major cause of liver disease and hepatocellular carcinoma worldwide. After the discovery of hepatitis C virus 3 decades ago, the identification of the structure of the viral proteins, combined with high-throughput replicon models, enabled the discovery and development of direct-acting antivirals. These agents have revolutionized patient care, with cure rates of more than 90%. We review the status of direct-acting antiviral therapies for hepatitis C virus infection and discuss remaining challenges. We highlight licensed compounds, discuss the potential to shorten therapy even further, and review different options for treatment failure and resistance. We also provide an overview of clinical experience with generic agents and evidence for their efficacy. Finally, we discuss the need for new drugs and outline promising targets for future therapies.<br /> (Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1528-0012
- Volume :
- 156
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Gastroenterology
- Publication Type :
- Academic Journal
- Accession number :
- 30342035
- Full Text :
- https://doi.org/10.1053/j.gastro.2018.10.024